The month ahead: September’s upcoming events
It’s a new term for biotech and its investors.
It’s a new term for biotech and its investors.
As a second-line zipalertinib filing approaches, Otsuka goes earlier and broader.
Jazz’s Chimerix buy faces its big test.
Data on J&J’s Tecvayli and Pfizer’s Elrexfio in relapsed multiple myeloma are due soon.
Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
The players are vying in the CD19 x CD20 Car-T arena.
The company sees an improvement with a Tecvayli/Talvey combo vs either monotherapy.